Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Atricure Inc (ATRC)

Atricure Inc (ATRC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating...

MS : 101.75 (-0.70%)
ATRC : 76.71 (+1.20%)
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates

AtriCure (ATRC) delivered earnings and revenue surprises of -9.09% and 15.91%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ATRC : 76.71 (+1.20%)
AtriCure Reports Second Quarter 2021 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results.

ATRC : 76.71 (+1.20%)
AtriCure to Participate at the Canaccord 41st Annual Growth Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating...

ATRC : 76.71 (+1.20%)
Mycoplasma Testing Global Market Report 2021: COVID-19 Growth And Change

Reportlinker.com announces the release of the report "Mycoplasma Testing Global Market Report 2021: COVID-19 Growth And Change" - https://www.reportlinker.com/p06103730/?utm_source=GNW

ATRC : 76.71 (+1.20%)
CRL : 440.45 (+0.75%)
CNMD : 130.03 (-1.25%)
MKKGY : 46.1300 (-0.54%)
OCPNY : 21.7700 (-1.27%)
SNN : 36.83 (-1.55%)
AtriCure to Announce Second Quarter 2021 Financial Results

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release second quarter 2021 financial...

ATRC : 76.71 (+1.20%)
AtriCure Names Two New Members to the Board of Directors

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. Telman and Maggie Yuen have been...

ATRC : 76.71 (+1.20%)
OGN : 34.03 (+0.80%)
MRK : 71.68 (-0.40%)
SRNE : 8.25 (+2.10%)
JCI : 74.59 (-0.96%)
ABT : 126.79 (-0.51%)
BA : 213.36 (unch)
PEN : 284.73 (-2.24%)
TMO : 596.80 (+6.49%)
BSX : 44.37 (-1.18%)
AtriCure (ATRC) Soars 8.8%: Is Further Upside Left in the Stock?

AtriCure (ATRC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in...

ATRC : 76.71 (+1.20%)
AtriCure's EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients

--Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for long-standing persistent Afib patients.

ATRC : 76.71 (+1.20%)
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates

AtriCure (ATRC) delivered earnings and revenue surprises of 7.32% and 5.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

ATRC : 76.71 (+1.20%)

Barchart Exclusives

US Stock Markets: Stop the Seasonal Madness
A popular theme on financial television these days is September is a seasonally bearish time for US stock markets. The evidence does not support this idea. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar